Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Astellas Pharma, Inc. (OTC: ALPMY).

Full DD Report for ALPMY

Recent News from (OTC: ALPMY)

Astellas Submits New Drug Applications for Approval of Gilteritinib for the Treatment of FLT3mut+ Relapsed or Refractory Acute Myeloid Leukemia
TOKYO , April 23, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas" ) today announced that it submitted on March 23, 2018 , a new drug application (NDA) for marketing approval of gilteritinib (generic name) in Japan for the tre...
Source: PR Newswire
Date: April, 23 2018 21:00
Key events next week - healthcare
Noteworthy events for the week of April 22 - 28 for healthcare investors. More news on: Navidea Biopharmaceuticals, Galectin Therapeutics, Inc., Eli Lilly and Company, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: April, 20 2018 07:43
Astellas Announces Sale of Certain Agensys Research Facilities to Kite, a Gilead Company
TOKYO , April 18, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , "Astellas" ) and Kite, a Gilead Company (Nasdaq: GILD, President and CEO: John Milligan , "Kite"), today announced that an agreement has been completed for the transfer of...
Source: PR Newswire
Date: April, 18 2018 18:00
3 Things In Biotech, March 27: Roche Rips, Loxo Rolls, Astellas Rams
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec...
Source: SeekingAlpha
Date: March, 28 2018 08:00
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
TOKYO and BOTHELL, Wash. , March 26, 2018 /PRNewswire/ --  Astellas Pharma Inc.  (TSE: 4503, President and CEO: Yoshihiko Hatanaka , "Astellas") and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrou...
Source: PR Newswire
Date: March, 26 2018 08:00
U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
NEW YORK and TOKYO , March 19, 2018 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka , "Astellas") announced today that a supplemental New Drug Application (sNDA) for XTANDI ® (enzalutamide) has been accepted ...
Source: PR Newswire
Date: March, 19 2018 16:15
3 Things In Biotech, March 18: Exelixis Lives, Astellas Digs Deeper, Alexion Equivocates
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Exe...
Source: SeekingAlpha
Date: March, 19 2018 08:00
3 Things In Biotech, March 12: Pfizer Passes, Voyager Regresses PD, New Astellas Approval
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec...
Source: SeekingAlpha
Date: March, 13 2018 08:37
3 Things In Biotech You Should Learn Today: February 16, 2018
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec...
Source: SeekingAlpha
Date: February, 16 2018 08:00
Astellas Acquires Universal Cells, Inc.
TOKYO , Feb. 13, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka , "Astellas") and Universal Cells, Inc. (CEO: Claudia Mitchell , "Universal Cells") today announced that Astellas has acquired Universal Cells. Astellas will gain Univers...
Source: PR Newswire
Date: February, 13 2018 20:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-04-2414.5014.4514.7214.3859,697
2018-04-2314.5514.4914.7814.4438,974
2018-04-2214.60514.6014.64514.5839,912
2018-04-2114.60514.6014.64514.5839,912
2018-04-2014.60514.6014.64514.5839,912

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-04-2316,07438,97441.2429Short
2018-04-2024,29132,51274.7140Short
2018-04-1913,93547,48829.3443Cover
2018-04-188,38561,71613.5864Cover
2018-04-1718,80043,69143.0295Short

* Short Mode

Short Analysis provided by Squeeze Report.


About Astellas Pharma, Inc. (OTC: ALPMY)

Logo for Astellas Pharma, Inc. (OTC: ALPMY)

Not available

 

Contact Information

 

 

Current Management

  • Masao Yoshida / CEO, President

Current Share Structure

     


    Recent Filings from (OTC: ALPMY)

    Filing to become effective immediately upon filing
    Filing Type: F-6EFFiling Source: edgar
    Filing Date: December, 21 2017
    Post-effective amendment to a previously filed F-6
    Filing Type: F-6 POSFiling Source: edgar
    Filing Date: September, 29 2017

     

     


    Daily Technical Chart for (OTC: ALPMY)

    Daily Technical Chart for (OTC: ALPMY)


    Stay tuned for daily updates and more on (OTC: ALPMY)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (OTC: ALPMY)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    The Subway Trader
    @TheSubwayTrader

     

     


    Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALPMY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of ALPMY and does not buy, sell, or trade any shares of ALPMY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/

     

     

    Release this Report to Investors

    Via Email

    Via Text

    Important

    If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us